Tysabri Progressive Multifocal Leukoencephalopathy Settlement: Statute of Limitations for Tysabri in Florida

Latest update (2026-07)

Tysabri (natalizumab) PML injury claims continue to be evaluated based on individual monitoring and diagnosis records. [source]

From General Health Awareness to Specific Legal Concerns

For decades, the domain of general health and science information has served as a foundational resource for public understanding of medical risks and therapeutic benefits. This legacy context has empowered individuals to make informed decisions about treatments, particularly those involving complex biological mechanisms. Within this framework, the transition from broad health awareness to specific occupational exposure concerns requires careful attention to the evolving landscape of pharmaceutical litigation and patient safety. In the realm of mass production, particularly in pharmaceutical manufacturing and clinical administration, the focus shifts from general health education to the practical realities of handling and distributing biologic therapies. One such therapy, Tysabri, has been associated with a rare but serious condition known as progressive multifocal leukoencephalopathy (PML). This connection has led to legal considerations for affected individuals, especially regarding the statute of limitations for filing claims in specific jurisdictions such as Florida. The pivot from general health context to occupational exposure concern is marked by the recognition that healthcare workers, patients, and their families may face distinct challenges when adverse effects emerge from therapeutic interventions. Understanding the legal timelines and procedural requirements for seeking compensation becomes paramount, particularly when exposure to risk occurs within professional or clinical settings. This transition underscores the importance of bridging general health literacy with specialized knowledge of liability frameworks, ensuring that those affected by PML in the context of Tysabri therapy can navigate the complexities of legal recourse within applicable time constraints.

Medical Evidence and Risk Factors for Tysabri-Associated PML

Tysabri (natalizumab) is a biologic therapy approved as monotherapy for relapsing forms of multiple sclerosis and for Crohn’s disease. Its use carries a well-documented risk of progressive multifocal leukoencephalopathy (PML), a severe opportunistic brain infection caused by the JC virus. For patients in Florida who have developed PML after Tysabri treatment, understanding the medical evidence and legal time limits is essential. The prescribing information for Tysabri contains a boxed warning stating that the drug increases the risk of PML, an infection that usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Three primary risk factors have been identified: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Healthcare professionals are instructed to monitor patients for any new signs or symptoms suggestive of PML and to withhold Tysabri immediately at the first such indication (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). PML typically occurs only in immunocompromised individuals and is caused by the JC virus (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Clinical presentation can include progressive neurological deficits such as weakness, visual changes, cognitive decline, and coordination problems. Diagnosis often involves MRI imaging and detection of JC virus DNA in cerebrospinal fluid. The mechanistic link between Tysabri and PML involves the drug’s action as an alpha-4 integrin antagonist, which prevents immune cells from crossing the blood-brain barrier, thereby reducing central nervous system immune surveillance and allowing JC virus reactivation. Because of the PML risk, Tysabri is available only through a restricted distribution program called the TOUCH Prescribing Program (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Under this program, prescribers must evaluate patients at specified intervals, including three months after the first infusion, six months after the first infusion, and every six months thereafter (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). They must also determine every six months whether patients should continue treatment and submit status reports to Biogen (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Cases of PML, hospitalizations due to opportunistic infections, and deaths must be reported to Biogen as soon as possible (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

Legal Considerations and Statute of Limitations in Florida

For patients who have developed PML after Tysabri treatment, settlement-related considerations may include whether the drug’s warnings were adequate. The boxed warning clearly states the increased risk of PML and identifies known risk factors (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). However, questions may arise about whether prescribers and patients were sufficiently informed about the magnitude of risk, especially for those with anti-JCV antibodies or prolonged therapy. The adequacy of warnings is a central issue in legal claims, as patients must demonstrate that the manufacturer failed to provide sufficient information about the risks. In Florida, the statute of limitations for personal injury claims, including those related to pharmaceutical injuries, is generally two years from the date the injury was discovered or should have been discovered with reasonable diligence. For PML, the timeline between Tysabri exposure and documented harm can vary. PML may develop months to years after starting Tysabri, and symptoms can be subtle initially. The discovery date is critical: the clock typically starts when the patient knew or reasonably should have known that PML was caused by Tysabri. This may be at the time of diagnosis, or later if the link was not immediately apparent. Patients who have been diagnosed with PML should consult with a legal professional promptly to determine whether their claim falls within the applicable time frame. Settlement considerations also involve the severity of harm. PML usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Affected patients may face substantial medical expenses, lost income, and reduced quality of life. Any settlement or legal claim would need to account for these damages. Additionally, the TOUCH program’s monitoring requirements may be relevant to whether the patient’s PML was detected early enough to mitigate harm. In summary, Tysabri-associated PML is a serious risk with known factors and a mandated monitoring program. For Florida patients, the statute of limitations is typically two years from discovery of the injury. Given the complexity of medical and legal issues, affected individuals should seek both medical care and legal advice as soon as possible.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the statute of limitations for Tysabri-related PML claims in Florida?

In Florida, the statute of limitations for personal injury claims, including those related to pharmaceutical injuries, is generally two years from the date the injury was discovered or should have been discovered with reasonable diligence. For PML, the discovery date is critical and may be at the time of diagnosis or later if the link to Tysabri was not immediately apparent. It is important to consult with a legal professional promptly to determine if your claim falls within the applicable time frame.

What are the primary risk factors for developing PML while on Tysabri?

According to the prescribing information, three primary risk factors have been identified: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Healthcare professionals are instructed to monitor patients for any new signs or symptoms suggestive of PML and to withhold Tysabri immediately at the first such indication.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Tysabri exposure and a confirmed Progressive Multifocal Leukoencephalopathy diagnosis may request an independent eligibility review. [Begin Assessment]

References

Tysabri Prescribing Information (DailyMed)

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.